A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
Open Access
- 25 July 2024
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (9) , 1157-1171
Abstract
Alopecia areata (AA) is an autoimmune disorder that manifests as nonscarring hair loss and imposes a substantial disease burden. The current study, using an e‐claims database, assesses the disease burden, comorbidities, treatment patterns, specialties involved in the diagnosis of AA, healthcare resource utilization (HCRU), and associated costs in privately insured patients with AA in Dubai, United Arab Emirates. The retrospective longitudinal secondary study was conducted using Dubai Real‐World Database e‐claims data during 01 January 2014 to 30 June 2022. Patients with at least one diagnosis claim of AA during the index period (01 January 2015–30 June 2021) with continuous enrollment (one or more AA/non‐AA claim in the post‐index period) were included in the analysis. The patients were stratified into subcohorts based on diagnosis code and treatment patterns, as mild, moderate‐to‐severe, and others. Demographics, comorbidities, treatment patterns, specialists visited, and HCRU were assessed. The study included 11 851 patients with AA (mean age: mild: 37 years; moderate‐to‐severe: 36 years), with a male predominance (mild: 77.6%; moderate‐to‐severe: 60.8%). The most prevalent comorbidities in the moderate‐to‐severe AA subcohort were autoimmune and T‐helper 2–mediated immune disorders, including contact dermatitis and eczema (62.1%), atopic dermatitis (36.1%), and asthma (36.1%). Most patients consulted dermatologists for treatment advice (mild AA: 87.4%; moderate‐to‐severe AA: 47.7%) and, notably, within 1 day of AA diagnosis. Topical steroids were frequently prescribed across cohorts, regardless of disease severity. Analysis of comorbidities among patients with AA indicated an additional HCRU burden among these subsets of patients. The median disease‐specific HCRU cost was higher for psychological comorbidities versus autoimmune and T‐helper 2–mediated immune disorders (US $224.99 vs US $103.70). There is a substantial disease and economic burden in patients with AA and associated comorbid conditions; therefore, investing in novel therapies that target the underlying autoimmune pathway may address the gap in effective management of AA.Keywords
This publication has 48 references indexed in Scilit:
- Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USADermatology and Therapy, 2022
- Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance ClaimsAdvances in Therapy, 2021
- Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature ReviewDermatology and Therapy, 2021
- Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective reviewArchives of Dermatological Research, 2021
- New and Emerging Therapies for Alopecia AreataDrugs, 2020
- Association of Out-of-Pocket Health Care Costs and Financial Burden for Patients With Alopecia AreataJAMA Dermatology, 2019
- Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia AreataJAMA Dermatology, 2019
- Quality of life in mild and severe alopecia areata patientsInternational Journal of Women's Dermatology, 2018
- Comorbidities in patients with alopecia areataJournal of the American Academy of Dermatology, 2017
- Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With Alopecia Areata in the United StatesJAMA Dermatology, 2013